Benefits
IBS in women — dose-ranging RCT
In IBS, B. infantis 35624 at 1 million / 100 million / 10 billion CFU once daily for 4 weeks was tested against placebo. Only 100 million CFU/day showed significant improvement in abdominal pain/discomfort, bloating/distention, sense of incomplete evacuation, straining, urgency, and passage difficulty. Critically, 1 million and 10 billion CFU showed no benefit: a narrow therapeutic window with a U-shaped dose-response, with under 5% withdrawal due to adverse events.
IBS subtype-broad efficacy
Efficacy has been reported across IBS subtypes (constipation-predominant, diarrhea-predominant, and alternating). This is clinically useful since many IBS patients shift between constipation- and diarrhea-predominant patterns or experience alternating symptoms.
IBS pilot study
A pilot study delivering 10 billion CFU/day via a malted milk beverage reported beneficial effects, but with documented methodological limitations (inadequate randomization, baseline imbalances, underpowered design). It motivated the dose-ranging follow-up.
Disease severity and quality of life (Sabaté 2022)
Trials using the reclassified B. longum 35624 taxonomy confirm efficacy for IBS disease severity and quality of life under the updated taxonomic naming.
Inflammatory cytokine modulation (gut-immune mechanism)
B. infantis 35624 modulates host inflammatory processes beyond the gut, including systemic cytokine effects. Mechanistic evidence supporting the strain's effects on the gut-immune axis.
Strain-specificity vs generic B. infantis
The clinical evidence applies specifically to strain 35624 — generic 'B. infantis' or 'B. longum' supplements do not have equivalent evidence. Strain-specific effects on cytokine modulation, gut adherence, and dose-response are well-characterized for 35624 but cannot be assumed for other strains.
Visceral antinociception
Visceral antinociceptive effects in a rat model of visceral hypersensitivity. Preclinical evidence supporting the gut-brain pain pathway mechanism for IBS abdominal pain reduction.
Mechanism of action
Strain-specific immunomodulation
B. infantis 35624 shows distinct immunomodulatory activity compared to other B. infantis or B. longum strains. Generic strain-level claims do not apply — the clinical evidence base is specific to 35624.
Gut-immune axis systemic modulation
The strain's effects extend beyond local gut inflammation to systemic cytokine modulation, likely contributing to the broader symptom relief beyond local gut symptoms in IBS.
Visceral antinociception
Preclinical evidence supports visceral antinociceptive effects via gut-brain axis pain pathway modulation. This is the mechanistic basis for the abdominal pain/discomfort reduction observed in IBS.
Adherence to human epithelial cells
Strain 35624 demonstrates adherence to human intestinal epithelial cells, supporting transient colonization and the local-effect mechanisms during the 4-week treatment window.
Dose-specific narrow therapeutic window (U-shaped response)
A hormesis-like effect has been documented: efficacy at 100 million CFU/day but no benefit at either 1 million or 10 billion CFU/day. This U-shaped dose-response is unusual and means commercial doses above the trial-effective level may not be equivalent, potentially less effective per the observed dose-response curve.
Survives gastric acidity
The strain survives gastric acid transit to reach the small intestine and colon viable — necessary for the local mechanisms to operate.
Clinical trials
Clinical evidence on Bifidobacterium infantis 35624 (Align® / Bifantis® / Meta Align®) for the indications and outcomes described.
Clinical population described in trial publication.
Whorwell PJ et al. 2006, Am J Gastroenterol 101:1581-1590, NCT00135031. Large-scale multicenter double-blind randomized placebo-controlled dose-ranging study. 362 female subjects with Rome II IBS, 4 weeks of 1 million / 100 million / 10 billion CFU/day or placebo. Only 100 million CFU/day showed significant improvement across abdominal pain/discomfort, bloating/distention, incomplete evacuation, straining, urgency, and passage difficulty. 1 million and 10 billion CFU/day showed no benefit. <5% AE withdrawal. International collaborators: Whorwell, Quigley, Kiely, Shanahan (APC Microbiome Cork). Industry-sponsored by Procter & Gamble.
Clinical evidence on Bifidobacterium infantis 35624 (Align® / Bifantis® / Meta Align®) for the indications and outcomes described.
Clinical population described in trial publication.
O'Mahony L et al. 2005. Pilot study via malted milk beverage delivery at 10 billion CFU/day. Reported beneficial effects but with documented methodological limitations: inadequate randomization, baseline imbalances, underpowered design. Motivated the subsequent dose-ranging clinical trial.
Clinical evidence on Bifidobacterium infantis 35624 (Align® / Bifantis® / Meta Align®) for the indications and outcomes described.
Clinical population described in trial publication.
Sabaté JM et al. 2022, World J Gastroenterol 28:732-744. IBS disease severity and quality-of-life trial confirming efficacy under the reclassified B. longum 35624 taxonomy. Recent confirmatory evidence.